Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery by Piazzini, Vieri et al.
20 December 2021
Chitosan coated human serum albumin nanoparticles: A promising strategy for nose-to-brain drug delivery / Piazzini,
Vieri; Landucci, Elisa; D'Ambrosio, Mario; Fasiolo, Laura Tiozzo; Cinci, Lorenzo; Colombo, Gaia; Pellegrini-Giampietro,
Domenico E.; Bilia, Anna Rita; Luceri, Cristina; Bergonzi, Maria Camilla. - In: INTERNATIONAL JOURNAL OF
BIOLOGICAL MACROMOLECULES. - ISSN 0141-8130. - ELETTRONICO. - 129(2019), pp. 267-280.
[10.1016/j.ijbiomac.2019.02.005]
Original Citation:
Chitosan coated human serum albumin nanoparticles: A promising strategy for
nose-to-brain drug delivery





Questa versione della pubblicazione è conforme a quanto richiesto dalle politiche dell'editore in materia di copyright.
This version of the publication conforms to the publisher's copyright policies.
(Article begins on next page)
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla
Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)
Availability:
This version is available at: 2158/1148862 since: 2021-04-02T11:15:13Z
Questa è la versione Preprint (Submitted version) della seguente pubblicazione:
FLORE





The aim of the present study was the development of human serum albumin nanoparticles (HSA NPs) 
as nose-to-brain carrier. To strengthen, the efficacy of nanoparticles as drug delivery system, the 
influence of chitosan (CS) coating on the performance of HSA NPs was investigated for nasal 
application. HSA NPs were prepared by desolvation technique. CS coating was obtained adding the 
CS solution to HSA NPs. The mean particle size was 24118 nm and 2618 nm and the -potential 
was -473 mV and +451 mV for HSA NPs and CS-HSA NPs, respectively. The optimized 
formulations showed excellent stability upon storage both as suspension and as freeze-dried product 
after 3 months. The mucoadhesion properties were assessed by turbidimetric and indirect method. 
NPs were loaded with sulforhodamine B sodium salt as model drug and the effect of CS coating was 
investigated performing release studies, permeation and uptake experiments using Caco-2 and 
hCMEC/D3 cells as model of the nasal epithelium and blood-brain barrier, respectively. Furthermore, 
ex vivo diffusion experiments have been carried out using rabbit nasal mucosa. Finally, the ability of 
the formulations to reversibly open tight and gap junctions was explored by western blotting and RT-
PCR analyzing in both Caco-2 and hCMEC/D3 cells. 
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The aim of the present study was the development of human serum albumin nanoparticles (HSA 
NPs) as nose-to-brain carrier. To strengthen, the efficacy of nanoparticles as drug delivery 
system, the influence of chitosan (CS) coating on the performance of HSA NPs was investigated 
for nasal application. HSA NPs were prepared by desolvation technique. CS coating was 
obtained adding the CS solution to HSA NPs. The mean particle sizes was 24118 nm and 
2618 nm and the -potential was -473 mV and +451 mV for HSA NPs and CS-HSA NPs, 
respectively. The optimized formulations showed excellent stability upon storage both as 
suspension and as freeze-dried product after 3 months. The mucoadhesion properties were 
assessed by turbidimetric and indirect method. NPs were loaded with sulforhodamine B sodium 
salt as model drug and the effect of CS coating was investigated performing release studies, 
permeation and uptake experiments using Caco-2 and hCMEC/D3 cells as model of the nasal 
epithelium and blood-brain barrier, respectively. Furthermore, ex vivo diffusion experiments 
have been carried out using rabbit nasal mucosa. Finally, the ability of the formulations to 
reversibly open tight and gap junctions was explored by western blotting and RT-PCR 
analyzing in both Caco-2 and hCMEC/D3 cells. 
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Most of the drugs, in particular hydrophilic molecules and high molecular weight compounds, 
are not favourably absorbed by the brain due to the presence of the blood-brain barrier (BBB) 
and blood-cerebrospinal fluid barrier, that cause a selective permeability to circulating 
molecules [1,2]. In the last years, the nose-to-brain (NTB) delivery is emerging strategy to 
overcome these barriers and delivery the drug directly into the brain. An increasing number of 
products are being developed and are reaching the market, such as vaccines, painkillers, anti-
migraine and anti-cancer drugs and hormones [3,4]. 
The intranasal route allows the administration of drugs both locally and systemically avoiding 
the typical gastrointestinal degradation of oral administration and the effect of hepatic 
metabolism. The rich vascularization of the nasal mucosa provides a series of unique attributes 
that can increase the safety, the patient compliance, the rate of absorption of the drug and, 
consequently, the speed of onset of the therapeutic effect. Furthermore, the nasal mucosa, is 
easily accessible compared to other membranes and it is a favourable entry route for both small 
and large molecules. The nasal bioavailability of small molecules is good and the drugs that are 
not absorbed orally can be conveyed to the nasal systemic circulation. Nasally administered 
drugs can rapidly reach the brain through different pathways: the first is the olfactory nerves, 
that represent the main direct pathway for the NTB drug delivery; then the trigeminal nerves, 
which have nerve endings in the respiratory epithelia; finally, the respiratory epithelium through 
which the drugs reach the circulation and subsequent cross the BBB [1,5,6].
However, the NTB delivery is characterized by several limitations such as the small volume of 
the nasal cavity, the mucociliary clearance, the enzymatic degradation, the low drug retention 
time, the potential nasomucosal toxicity, the technique of drug administration and deposition 
and the necessity of a suitable delivery device [4,7,8]. 
To overcome these drawbacks, pharmaceutical nanotechnologies appear as an ideal formulation 
strategy for the NTB delivery [1,4,6-9]. In this context, the aim of the present study was the 
development of human serum albumin nanoparticles (HSA NPs) as NTB carrier and the 
investigation of the effect of chitosan (CS) coating on their performance, in particular with 
respect to the surface and mucoadhesive properties, stability, drug release modulation, 
biocompatibility and permeability. 
HSA is an endogenous protein, non-toxic, non-immunogenic, biodegradable and 
biocompatible. Moreover, it displays good mucoadhesive properties, suitable for prolonging 






























































properties and it can show conformational modifications to increase its stability [11,12]. 
Furthermore, as reported in literature, albumin is an ideal substance for the development of 
nanocarriers with the aim of increasing bioavailability, stability and pharmacological effects of 
synthetics and plant-derived molecules [13-18]. 
HSA NPs were employed for the NTB delivery of the anti-Alzheimer drugs tacrine and R-
flurbiprofen [19,20]. 
CS, a polysaccharide derived from deacetylation of chitin, was also employed for its ability to 
reversibly open tight junctions, with the potential to increase the drug permeation across the 
nasal mucosa and the extracellular transport along the olfactory and trigeminal nerves. Besides, 
positively charged CS can increase the drug residence time of the loaded drug in the nasal 
cavity, due to the electrostatic interactions with the negatively charged epithelial cells or the 
ability to absorb water from the mucus layer, forming a gel-like layer that increases the contact 
with the site of absorption [4,21,22,23]. CS NPs and other CS derived formulations were 
investigated for nose to brain delivery [22] 
Various HSA and CS NPs have been utilized to deliver anticancer agents at the tumor. Proteins 
and polysaccharides-based nanocarriers have great potential as drug delivery based on their 
biocompatibility, biodegradability, ease of functionalization, improved biodistribution and 
reduced toxicity effects [21,24,25]. The main application of CS coated formulations is for the 
oral administration. CS-coated PLGA and PCL NPs were considered for nasal delivery [5,26]. 
CS-coated HSA (CS-HSA NPs) nanoparticles functionalized by MUC1 aptamer have 
previously reported to load paclitaxel and investigate the specific targeting potential in human 
breast tumor cells, MCF7 and T47D [21].  However, the present study is the first application of 
CS-HSA NPs for NTB delivery. The surface charges modification of NPs from negative, with 
HAS, to positive in the presence of CS have also considered due to its important effect on the 
interaction with cell membranes and on cellular uptake [21]. 
Developed HAS NPs and CS-HAS NPs were physically and chemically characterized by Light 
Scattering techniques (DLS and ELS), Transmission Electron Microscopy and High 
Performance Liquid Chromatography. The freeze-drying process was evaluated as technique to 
increase NPs stability. The mucoadhesion properties were assessed through the turbidimetric 
method and the evaluation of the change in the -potential value. HSA NPs and CS-HSA NPs 
were loaded with sulforhodamine B sodium salt (SulfB) as a model of a hydrophilic drug 
(SulfB-HAS NPs and SulfB-CS-HAS NPs) and the effect of CS coating was investigated with 






























































hCMEC/D3 cells as model of the nasal epithelium and BBB, respectively [15,23,27-30]. 
Furthermore, ex vivo diffusion experiments were performed using rabbit nasal mucosa in a 
Franz-type permeation apparatus. The possible effects of the two formulations on tight and gap 
junctions expression were assessed by exposing Caco-2 and hCMEC/D3 cells to HSA NPs and 
CS-HSA NPs and by measuring the expression of Tight Junction Protein 1 (TJP1, also known 
as zona occludens protein-1), at the protein and RNA levels.
2. Material and methods
2.1 Material
Sigma-Aldrich (Milan, Italy) provided all chemicals, analytical grade and HPLC grade 
solvents. Human serum albumin (Sigma-Aldrich, Milan, Italy; cat n. SPR6182, mol wt 66.4 
kDa). Chitosan low molecular weight (Sigma-Aldrich, Milan, Italy; cat n. 448869, mol wt. 
50,000-190,000 Da, viscosity 20-300 cP, 1 wt. % in 1% acetic acid, 25 °C, Brookfield). Mucin 
from porcine stomach (Sigma-Aldrich, Milan, Italy; cat n. M1778, Type III, bound sialic acid 
0.5-1.5 %). Water was purified by a Milli-Qplus system (Millipore Milford, CT, USA). 
Phosphotungstic acid (PTA) was from Electron Microscopy Sciences (Hatfield, PA, USA). 
Dialysis kit was from Spectrum Laboratories, Inc. (Breda, The Netherlands).
2.2 Methods
2.2.1 Preparation of human serum albumin nanoparticles
HSA NPs were prepared by the desolvation-coacervation technique [31,32], with some 
modifications. HSA (30 mg) was dissolved in 3 mL of 10 mM NaCl solution under magnetic 
stirring. The pH value was adjusted between 8 and 9 with NaOH 0.1 N. Then, ethanol was 
added at a constant rate using a syringe until turbidity appeared in the solution. The obtained 
coacervates were hardened by the addition of 5% glutaraldehyde solution, corresponding to 
100% of the amount required for the cross-linking of the 60 amino groups of HSA. After 2 h 
under magnetic stirring at room temperature, ethanol was vacuum evaporated, and the pellet 
was redispersed in distilled water.
In addition, fluorescent NPs (SulfB-HAS NPs) were prepared, adding sulforhodamine B 
sodium salt (ex=565 nm, em=586 nm in water, SulfB) to the HSA solution (final concentration 
0.1 mg/mL). The resulted mixture was incubated for 2 h under magnetic stirring at 500 rpm, 






























































2.2.2 Preparation of chitosan-coated nanoparticles
CS-HSA NPs were obtained exploiting the ionic interactions between negatively charged HSA 
NPs and positively charged CS [21]. Firstly, CS was dissolved in 1% v/v glacial acetic acid at 
the concentration of 1 mg/mL. After 24 h under stirring at room temperature, the solution was 
filtered through a 0.45 m membrane and then, the pH was adjusted to 4.5 with NaOH diluted 
solution (0.1 N). Afterwards, 5 mL of CS solution was added to an equal volume of HSA NPs 
suspension under magnetic stirring at a speed of 250 rpm at room temperature. The stirring was 
maintained for 15 min to allow the stabilization of the CS coating. 
SulfB-CS-HSA NPs were prepared by adding CS solution to SulfB-HAS NPs suspension.
2.2.3 Physical characterization
Particle size, the polydispersity index (PdI) and ζ-potential have been measured a Zsizer 
Nanoseries ZS90 instrument (Malvern Instrument, Worcestershire, UK). The analyses were 
performed in triplicate.
2.2.4 TEM
The morphological characterization of NPs was analyzed by transmission electron microscopy 
(Jeol 1010, Tokyo, Japan). The samples were prepared as previously reported [29]. They were 
properly diluted with distilled water, then they were dropped on a 200 mesh carbon film-
covered copper grid and negatively stained with a phosphotungstic acid aqueous solution (1% 
w/v). After drying, the grid containing the samples were observed with the TEM.
2.2.5 NPs yield determination
In order to evaluate the amount of HSA transformed into nanoparticles, 1.5 mL of HSA NPs 
and CS-HSA NPs were centrifuged at 21773 x g for 45 min. Then, the obtained supernatants 
were analyzed by HPLC [33]. 
The chromatograph was a HP 1200 liquid chromatograph coupled with a diode-array-detector 
(DAD) (Agilent Technologies, Santa Clara, CA, USA). The column was a Luna Omega Polar 
(150 mm × 3 mm, 5 µm) (Agilent Technologies, Santa Clara, CA, USA). The mobile phases 
were: (A) formic acid/water pH 3.2 and (B) acetonitrile. The flow rate was 0.5 mL/min. The 
multi-step linear solvent gradient applied was: 0-2 min, 90% A, 10% B; 2-7 min, 90-60% A, 
10-40% B; 7-17 min, 60-30% A, 40-70% B; 17-20 min, 30-10% A, 70-90% B; 20-22 min 10% 






























































out at a wavelength of 280 nm [33]. The linearity was determined on five concentration levels 
of HSA dissolved in distilled water (from 0.1 to 1 mg/mL) with three injections for each level. 
The coefficient of linear correlation is above than 0.999.
2.2.6 Determination of Encapsulation Efficiency (EE%)
EE% was determined by the dialysis bag method. The membrane (cut-off 3.5 kD) was filled 
with 2 mL of the samples, and kept for 1 h in 1 L of distilled water, to remove the free SulfB. 
Then the samples were diluted with a CH3CN/H2O 70:30 mixture, sonicated and analyzed by 
HPLC. SulfB analyses were performed using the same instrument, column and analytical 
method reported for HSA analysis, but the chromatograms were acquired at 560 nm. The EE% 
has been calculated as follows:
Encapsulation efficiency % =
SulfB encapsulated
Total SulfB × 100
2.2.7 Nanoparticle freeze-drying 
An aliquot of HSA NPs and CS-HSA NPs was lyophilized as such, other three aliquots were 
freeze-dried in the presence of D-Glucose anhydrous or D-Mannitol or D-Sucrose as 
cryoprotective agents (2% w/v) [34]. After the freeze-drying process, each sample was 
reconstituted with the original volume of distilled water, vortexed for few minutes to ensure the 
complete redispersion of the powder [34] and analyzed for particle size, polydispersity and -
potential.
2.2.8 Stability studies
Stability studies were conducted for three months. Particle size, PdI and ζ-potential were 
evaluated at 4°C for HSA NPs and CS-HSA NPs suspensions, and at room temperature for 
freeze-dried products. 
2.2.9 Mucoadhesion properties
To evaluate and compare the mucoadhesion properties of both NPs in the presence of mucin, 
the turbidimetric method [35] and the evaluation of the -potential (indirect method) were 
applied [36,37]. An equal volume of nanoparticles suspension and 1% w/v mucin aqueous 






























































water bath for 1 h at 37°C. The turbidity of the mixtures was evaluated spectrophotometrically 
at = 500 nm. The absorbances of individual mucin and nanoparticle suspensions were also 
recorded. The interaction between mucin and HSA NPs or CS-HSA NPs was calculated using 
the following equation: 
A = A – Atheor
where A is the absorbance difference, A is the effective absorbance of HSA NPs-mucin and 
CS-HSA NPs-mucin mixtures and Atheor represents the sum between the individual absorbance 
of mucin and nanoparticles suspensions. If A = 0, no interactions occur, whereas if A >> 0 
there is a strong interaction between nanoparticles and mucin.
The -potential was measured as previously reported.
2.2.10 In vitro release studies
Dialysis bag method was applied for the in vitro release studies in physiological pH conditions 
(PBS pH 7.4). For these studies regenerated cellulose membranes (cut-off of 3.5 kD) were 
chosen for retaining the nanoparticles and allowing for the diffusion of the entrapped compound 
into the dissolution medium. SulfB-HAS NPs, SulfB-CS-HSA NPs or SulfB aqueous solution 
(2 mL) were added into dialysis membranes and placed in 200 mL of release medium. Thus, 
the systems were incubated at 37°C with stirring at 150 rpm. At predetermined time intervals 
(0, 0.5, 1, 2, 4, 5, 8 and 24 h) 1 mL of the medium was withdrawn and replaced with the same 
volume of fresh release medium maintained at 37°C to preserve sink conditions. SulfB released 
at each time interval was quantified using HPLC. All experiments were performed in triplicate. 
Different mathematical models were used to understand the kinetic and the mechanism of drug 
release from HSA NPs and CS-HSA NPs. The best-fitted model was defined based on the 
highest R2 value of the release curve.
2.2.11 Experiments with Caco-2 cells
Caco-2 cell line
Caco-2 cells (human colorectal adenocarcinoma) were from American Tissue Type Culture 
Collection (Manassas, VA, USA) and cultured in Dulbecco’s modified Eagle’s medium with 
20% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin in 5% CO2 at 37 °C 































































The cell viability was assessed using MTS assay, as previously described [38]. The cells were 
exposed to HSA NPs and CS-HSA NPs at different dilutions (from 1:10 to 1:40) for 2 and 24 
h. The relative cell viability was expressed as a percentage of the untreated control group.
Transport Studies
Caco-2 cells were seeded into 12-well PET transwell plates (1.13 cm2 growth surface area and 
pore size 0.4 µm, Greiner Bio-One, Milan, Italy) at a density of 2 × 104 cells/cm2. A confluent 
monolayer was obtained after 21 days. 
SulfB-HSA NPs and SulfB-CS-HSA NPs diluted 10 times were incubated for 4 h in the apical 
compartment. Lucifer Yellow (LY) was used to check the integrity of the cellular layer during 
the permeability test [39]. At 0 (before sample addition), 60, 120, 180 and 240 min, samples 
were taken from the basal compartment of each transwell plate and fresh HBSS was added. The 
SulfB concentration was determined by HPLC. 
Mucin staining
To highlight the presence of mucin production on the Caco-2 cells monolayer, cells were seeded 
and cultured for 21 days in specific chamber-slide for cytological analysis (X-well tissue culture 
chambers, Sarstedt, Verona, Italy). After 21 days of culture, cells were fixed in 4% 
paraformaldehyde for 15 minutes at room temperature. Slides were rinsed in 3% acetic acid 
solution and incubated for 2 hours in 1% alcian-blue solution, then, were rinsed in H2O, 
oxidized for 10 minutes in 1% periodic acid solution and incubated for 10 minutes in Schiff 
reactive. Slides were finally rinsed in H2O and washed three times in 0.5% sodium bisulfite 
solution, dehydrated and mounted. Nuclei were counterstained with hematoxylin for 30 
seconds. 
Cell uptake Studies
Caco-2 cells were pre-incubated with sodium azide (1 µM), chlorpromazine (15 M), and 
indomethacin (25 M) for 30 min followed by the addition of SulfB-HSA NPs or SulfB-CS-
HSA NPs 1:10 for 1 h, or maintained at 4°C during the NPs exposure. At the end of the 































































2.2.12 Experiments with hCMEC/D3 cells
hCMEC/D3 cell line
The brain microvascular endothelial cell line hCMEC/D3 (Millipore) derives from human 
temporal lobe microvessels isolated from epilepsy control obtained by medical surgery. Cell 
were seeded and grown as previously reported [29]. Cell were maintained at 37°C in an 
incubator in atmosphere of humidified air and 5% CO2 and the EndoGRO medium 
supplemented with 1 ng/mL FGF-2 was changed thrice a week. Cells were passaged at least 
twice before use. Accumax TM Cell Counting Solution in DPBS was used to split the confluent 
cells.
MTT assay
The cell viability after HSA NPs and CS-HSA NPs exposure in hCMEC/D3 cell was assessed 
by MTT assay [40,41]. After pre-coated of the 24-well plate with Collagen Type I, Rat Tail, 
the cells were seeded and maintained until they were approximately 70-80% confluent. HSA 
NPs and CS-HSA NPs were incubated at different concentrations (diluition 1:10, 1:100 and 
1:500) of the formulation for 2 and 24 h in the complete medium (EBM-2). A part of the 
medium of each treatment was taken and preserved for LDH assay, and cells were incubated 
with MTT at the concentration of 1 mg/mL. Finally, DMSO was used to dissolve MTT 
formation and absorbance was recorded at 550 and 690 nm. EBM-2 was used as posite control 
and Triton X-100 as negate control and the cell viability was expressed as a percentage 
compared to the cells incubated only with EBM-2. 
LDH assay
The extent of cell death after HSA NPs and CS-HSA NPs exposure was quantitatively evaluated 
by measuring the amount of LDH release from injured cells, as previously described [29]. The 
LDH level corresponding to complete cell death was obtained in the presence of triton X-100 
(positive control). All the values were expressed as a percentage compared to TX release, EBM-
2 was used as the negative control. 
hCMEC/D3 cell culture for transwell permeability studies
High-density pore (2 x106 pores/cm2) transparent PET membrane filter inserts (0.4 μm, 23,1 
mm diameter, Falcon, Corning BV, Netherlands) in 6-well plates were used for all transcytosis 






























































filter inserts, the cells were seeded onto the apical side of the inserts at a density of 6 x 104 
cells/cm2. hCMEC/D3 monolayers were used to perform the permeability assay for SulfB-HSA 
NPs and SulfB-CS-HSA NPs. The integrity of the monolayer cells was controlled using 
fluorescein sodium salt (NaF) at a concentration of 10 μg/mL [15], and by observation of 
cultures under phase-contrast microscopy [28] using an inverted microscope (Olympus IX-50; 
Solent Scientific, Segensworth, UK) with (20X). For permeability studies, SulfB-HSA NPs and 
SulfB-CS-HSA NPs, diluted 10 times were tested and incubated for 1, 2 and 3 h in the apical 
donor compartment. NaF and SulfB were quantified in both in compartments by HPLC-FLD 
or HPLC-DAD analyses. 
Cell uptake Studies 
Sodium azide (1 M), chlorpromazine (15 M) and indomethacin (25 M) were used to 
understand the uptake mechanism of the developed nanoparticles. The drugs were preincubated 
for 30 min before the addition of SulfB-HSA NPs or SulfB-CS-HSA NPs for 2h at the dilution 
of 1:10. The quantity of SulfB was measured on cellular lysate by HPLC analyses at the end of 
the test. 
Western blotting
hCMEC/D3 and Caco-2 cells were seeded into 6-well plates at a density of 1.2 × 106 cells/cm2 
and after exposure to HSA NPs and CS-HSA NPs at the dilution of 1:10 for 2 h, the cells (1 
well/sample) were washed with cold 0.01 M PBS, pH 7.4 and were transferred and dissolved 
in a tube containing 1% SDS. The Pierce (Rockford, IL, USA) BCA (bicinchoninic acid) 
Protein Assay Total was used to quantify the protein levels. Lysates (20 μg/lane of protein) 
were resolved by electrophoresis on a 4-20% SDS-polyacrylamide gel (Bio-Rad Laboratories, 
Hercules, CA, USA) and transferred onto nitrocellulose membranes. Blots were blocked for 1 
h at room temperature in 20 mM Tris-buffered saline, pH 7.6-0.1% Tween 20 (TBS-T) 
containing 5% non-fat dry milk, and then incubated overnight at 4°C with rat monoclonal 
antibodies against ZO1, mouse monoclonal antibodies against claudin-5 (all from Santa Cruz 
Biotechnology,  CA, U.S.A) diluted 1:300 in TBS-T containing 5% non-fat dry milk or 
polyclonal-rabbit antibody against Ve-Chaderin (from Cell Signaling Technology, Beverly, 
MA, USA) diluted 1:1000 in TBS-T containing 5% bovine serum albumin. The loading control 
anti-β-actin antibody was monoclonal from Sigma (St Louis, MO, USA). Immunodetection was 






























































donkey, Amersham Biosciences, UK) conjugated to horseradish peroxidase in TBS-T 
containing 5% non-fat dry milk. Membranes were washed with TBS-T and then reactive bands 
were detected using chemiluminescence (ECLplus; Euroclone, Padova, Italy). Quantitative 
analysis was performed using the QuantityOne analysis software (Bio-Rad, Hercules, CA, 
USA).
RT-PCR
hCMEC/D3 and Caco-2 cells were seeded into 12-well plates at a density of 1.0 × 105 cells/cm2.  
After exposure to HSA NPs and CS-HSA NPs at the dilution of 1:10 for 2 h, the cells were 
washed with Dulbecco-s phosphate-buffered saline. The Nucleo Spin® RNA kit (Macherey-
Nagel, Bethlehem, USA) were used to extractthe total RNA from cell lysates. 
For first-strand cDNA synthesis, 1 µg of total RNA from each sample was reverse-transcribed 
by using the RevertAid RT Kit (Thermo Scientific, Waltham, MA USA). Primers were 
designed on the basis of the GenBank sequences for homo sapiens Tight Junction Protein 1, 
TJP1 (NM_003257.4): forward primer 5’-GGGAGCACATGGTGAAGGTAA-3’, reverse 
primer 5’- ATCACAGTGTGGTAAGCGCA-3’.  GAPDH was co-amplified as reference gene: 
forward primer 5’-CCCTCAAGGGCATCCTGGGCT-3’, reverse primer 5’-
GCAGGGACTCCCCAGCAGTGA-3’. PCRs were carried out using 1 μl of cDNA in a 25 µl 
total volume containing 1x PCR buffer, 0.5 mM dNTPs, 8 ng/µl of primer, 0.1 ng/µl of  GAPDH 
primers and 1.25 units of Taq polymerase (Dream Taq, Carlo Erba, Milan, Italy). The PCR 
conditions were: 95°C for 5 min and 30 cycles at 95oC for 30 sec, 60oC for 30 sec and 72oC for 
55 sec. PCR products were separated on a agarose gel (1.8%) and visualized by Safeview 
staining (Euroclone, Milan, Italy). Gel images were captured by an UVIdocHD2 acquired 
system (Eppendorf, Milan, Italy) and the intensity of the bands were analysed with the 
Quantity-One software (Bio-Rad, Segrate, Milan, Italy).
2.2.13 Ex vivo transport experiments across rabbit nasal mucosa
Ex vivo transport experiments were performed using rabbit nasal mucosa in a Franz-type 
diffusion apparatus (0.58 cm2 permeation area, VETROTECNICA S.r.l., Padova, Italy) [42-
44]. On the day of the experiment, rabbit heads were collected from a local slaughterhouse 
(Pola S.r.l, Finale Emilia, Italy) and transported to the laboratory in a refrigerated box. The 
extraction procedure, completed within 2 h from the animal’s death, and the protocol to treat 






























































Before introducing the NPs in the donor compartment, the receptor compartment was filled 
with PBS and the assembled system was allowed to equilibrate at 37◦C for half an hour. 
In particular, SulfB-HSA NPs, SulfB-CS-HSA NPs and SulfB aqueous solution were tested by 
maintaining the concentration of SulfB constant in all the samples (0.1 mg/mL).
The experiments were carried out over a 4 h and 24 h period of time. This experiment duration 
was consistent with the data in literature about tissue viability and drug transport experiments 
across animal excised nasal mucosa, employing nano-drug delivery systems [46-51]. 
At predetermined time points, a volume of receptor solution (0.5 mL) was withdrawn, and the 
receptor compartment refilled with an equivalent volume of fresh PBS. At the end of the 
experiment, the mass balance (sum of the amounts of SulB recovered from receptor, donor and 
membrane) was calculated. For this aim, the residual formulation on the membrane was 
quantitatively recovered by rinsing the donor compartment with PBS. In addition, SulfB 
retained at the membrane nasal mucosa was extracted with distilled water using an IKA T25 
digital Ultra-Turrax (IKA-Works, Staufen im Breisgau, Germany) for 10 min and then an 
ultrasound bath for 30 min. All the samples were analyzed by HPLC.
The flux of SulfB across the mucosa in steady-state conditions was calculated according to the 
solution of Fick Equation [43]. 
2.2.14 Statistical analysis
The experiments were performed in triplicate. The results were expressed as a mean ± S.D. 
(standard deviation). Statistical analyses cells viability, permeability studies and cellular uptake 
were performed using one-way ANOVA followed by the post hoc Tukey’s w-test for multiple 
comparisons. GRAPH-PAD PRISM v. 5 for Windows (GraphPad Software, San Diego, CA, 
USA) was applied to all statistical calculations. A P value < 0.05 was considered significant.
3. Results and Discussion 
3.1 HSA NPs characteristics
HSA NPs were obtained by the desolvation-coacervation technique [31,32]. The hydrodynamic 
diameter of the nanoparticles is one of the most crucial parameters that affect the nose-to-brain 
absorption. Indeed, only small particles can be transported to the brain via the olfactory or the 






























































9 considering that the particle size decreased with increasing pH [32]. NaCl was selected 
because other salts interfere with the desolvation and cross-linking process [32,52].
Ethanol was used as desolvating agent due to its dielectric constant, dipole moment and 
solubility parameter that make it an ideal solvent to enter into the hydrophobic region of HSA, 
disrupt the hydrophilic layer of the protein in water, and to induce the denaturation of HSA and 
consequently the formation of NPs [53]. Besides, ethanol is less toxic compared to other organic 
solvents proposed as desolvating agents, i.e., acetone, methanol and acetonitrile [54,55]. 
Glutaraldehyde aqueous solution was chosen as cross-linker agent [32]. Among the different 
tested concentrations (from 50% to 200% of the calculated amount required for the cross-
linking of the amino groups of HSA), the best results concerning particle size, homogeneity, 
yield and reproducibility were obtained with the 100% concentration (Table 1).
The morphological appearance of NPs confirmed the presence of spherical HSA NPs with 
uniform size distribution in the range of 230-250 nm, according to the DLS measurements 
(Figure 1).
The surface charge of the developed HSA NPs was negative due to the presence of the terminal 
carboxyl groups of the protein. The high -potential value indicates the presence of strong 
repulsive forces which can prevent the aggregation of the NPs, increasing the stability of the 
formulation (Table 1). Besides, the negative surface charge is crucial for further surface 
modification step.
Table 1. Physical and chemical characterization of empty and SulfB-HSA NPs. Data displayed 
as mean ± SD; n=3.
Sample Size (nm) PdI -potential (mV) EE% Yield %
HSA NPs 241  19 0.06  0.04 -47  3 - 93  1
SulfB-HSA NPs 244  12 0.11  0.02 -44  5 65  2 95  2
The nanoparticle yield, determined by HPLC analyses as previously reported in the literature 
[33], was very high, indicating that almost all HSA was converted into NPs. Thus, the obtained 
results demonstrated the success of the preparative process.
SulfB, a hydrophilic fluorescent dye, was incorporated into HSA NPs (SulfB-HSA NPs) as 
hydrophilic drug model to perform release studies and in vitro experiments with Caco-2 and 






























































selected because it does not have a pH-dependent absorption or fluorescence over the range of 
3 to 10 and it is highly soluble in the media employed in the in vitro/ex vivo assays. The 
incorporation of SulfB did not negatively affect the size and homogeneity of HSA NPs, as 
reported in Table 1.
3.2 CS-HSA NPs characteristics
CS-HSA NPs were obtained by the electrostatic interaction between negatively charged HSA 
NPs and positively charged CS [21]. Low molecular weight CS was used according to 
Bonaccorso [5]. The increase in particle size and the inversion of -potential value clearly 
indicated the interaction between HSA NPs and CS [37] (Table 2). The high -potential is 
related to a stable formulation in which the electrostatic repulsions prevent the aggregation. The 
positive surface charge of CS-HSA NPs is also fundamental for further interaction with 
negatively charged cell membranes and to improve the mucoadhesive properties.
Different CS concentrations were tested (from 1 mg/mL to 3 mg/mL). As CS concentration 
increased, particle enlargement (greater than 300 nm) and broadening of the size distribution 
(PdI > 0.3) were observed, while the -potential remained unchanged. Eventually, CS was 
employed at the concentration of 0.1 mg/mL (Table 2).
TEM micrographs provided information on morphology and dimensions of the NPs and showed 
the presence of CS on the surface of HSA NPs as a grey shell (Figure 2) [37,56,57]. 
Dimensional analysis with TEM (220-230 nm) correlated with DLS values. The little difference 
between the results obtained with the two analytical techniques could be due to different sample 
preparation: the dehydration of CS NPs in the case of TEM leads to measurement of the particle 
which is smaller than hydrodynamic particles, as previously reported [28]. The other 
physicochemical properties of HSA NPs such as PdI, EE% and the nanoparticle yield were not 
affected by the presence of CS. 
Table 2. Physical and chemical characteristics of empty and SulfB-CS-HSA NPs. Data 
displayed as mean ± SD; n=3.
Sample Size (nm) PdI -Potential (mV) EE% Yield %
CS-HSA NPs 261  8 0.10  0.07 +45  1 - 94  1






























































3.3 Nanoparticles freeze-drying 
The freeze-drying process improves the long-term stability of nanoparticles and limits the 
microbial proliferation caused by the presence of the aqueous medium. In this perspective, HSA 
NPs and CS-HSA NPs were freeze-dried without cryoprotectants and in the presence of sugars 
or sugar alcohols such as glucose, sucrose and mannitol. Fast freezing rate with liquid nitrogen 
was preferred because it avoids the formation of large ice crystals, which could damage the NPs 
and reduces their aggregation [59,60]. In the absence of cryoprotectant, a significant increase 
in size and a loss of size homogeneity were observed for both formulations (Table 3). This 
result confirmed the advantage of cryoprotectants in preventing the aggregation of albumin NPs 
during the freeze-drying process [34].
Table 3. Physical parameters of HSA NPs and CS-HSA NPs after the freeze-drying process 
without and with different cryoprotectants. Data displayed as mean ± SD; n=3.
All the cryoprotectants were tested at the concentration of 2% w/v. The best performance in 
terms of technological aspects was obtained with sucrose (Table 3). A slight size increase was 
found, nevertheless the NPs maintained physical characteristics suitable for the intranasal 
application.
Non-reducing compounds such as mannitol and sucrose are generally preferred to avoid 
potential Maillard reaction of the cryoprotectant with the protein [61]. Sucrose resulted better 
than mannitol in particular for CS-HSA NPs, so it was selected for storage stability studies. A 
possible reason for this result could be the tendency of mannitol to crystallize during the freeze-
drying process [61].
Freeze-dried product Size (nm) PdI -potential (mV)
HSA NPs > 500 nm > 0.5 -
HSA NPs + Glucose 269  3 0.05  0.01 -45  2
HSA NPs + Mannitol 262  5 0.06  0.01 -44  1
HSA NPs + Sucrose 261  1 0.06  0.01 -45  1
CS-HSA NPs > 500 nm > 0.5 -
CS-HSA NPs + Glucose 276  5 0.12  0.02 +31  1
CS-HSA NPs + Mannitol 285  2 0.11  0.01 +17  3






























































3.4 Storage stability studies
Physical stability of HSA NPs and CS-HSA NPs as suspension and as freeze-dried product was 
monitored during three months. Both HSA NPs and CS-HSA NPs suspensions resulted stable 
at 4°C. The final values of particle size and PdI for HSA NPs were 238 ± 5 and 0.10 ± 0.01, 
respectively, while for CS-HSA NPs they resulted 265 ± 2 and 0.11 ± 0.01, respectively. No 
significant changes were also found for ζ-potential after 3 months of storage: -47 ± 1 for HSA 
NPs and +43 ± 2 for CS-HSA NPs.
A similar study was performed on freeze-dried NPs. Both products maintained almost the same 
initial physical characteristics: size 260 ± 3 nm, PdI 0.07 ± 0.01 and -potential of −40 ± 1 mV, 
in the case of HSA NPs; and size 265 ± 1 nm, PdI 0.06 ± 0.01 and -potential of +37 ± 2 mV, 
in the case of CS-HSA NPs. These data demonstrate that the developed NPs can be stored as 
suspension in the fridge and potentially even at room temperature as freeze-dried products for 
long periods.
Stability of SulfB loaded NPs was also considered. They were physically and chemically stable 
at 37°C and in the light for three days. These results were also important for the subsequent in 
vitro and ex vivo experiments.
3.5 Mucoadhesion properties
Turbidity analyses and the evaluation of the -potential were synergistically applied to 
investigate and compare the mucoadhesion properties of CS-HSA NPs and uncoated NPs.
As clearly reported in Figure 3, a significant increase in absorbance difference (A) was found 
in the case of CS-HSA NPs indicating a strong interaction between positively charged amino 
groups present in CS and the negatively charged carboxyl and sulphate groups of the mucin 
[36, 62]. -potential analyses confirmed the data obtained by the turbidimetric method. Positive 
charges of CS-HSA NPs were neutralized by the negative charges of mucin (Figure 4). On the 
other hand, uncoated NPs remain negatively charged once the interaction with mucin occurs at 
lower extension [36,63]. 
3.6 In vitro release experiments
In vitro release profiles of the dye from the aqueous solution, the SulfB-HSA NPs and the 
SulfB-CS-HSA NPs suspensions are reported in Figure 5. In the case of the solution, 100% of 
SulfB was released after 2 h, while in the case of both formulations the immediate release of 






























































finding because it suggests that the drug leakage during in vivo delivery would be minimal. The 
release of SulfB from CS-HSA NPs started quite slower respect to HSA NPs, then, after about 
four hours, the release profiles of the formulations became similar as a consequence of CS 
hydration and swelling (Figure 5) [51,64].
As previously reported, the release kinetics of SulfB, employed as a model of a hydrophilic 
drug, were analysed by Hixson-Crowell, Higuchi, first- and zero-order mathematical models. 
The results revealed that the release of SulfB from both formulations was diffusion-controlled, 
as indicated by higher R-squared (R2) values in the Higuchi model (0.839 for HSA NPs and 
0.884 for CS-HSA NPs). 
When the release data were analyzed using the Korsemeyer–Peppas model, the values of the 
diffusional exponent n were found to be 0.68 and 0.67 for HSA NPs and CS-HSA NPs, 
respectively, demonstrating that the SulfB release follows a non-Fickian diffusion mechanism.
3.7 Caco-2 experiments
Caco-2 cell line was used as model of the nasal epithelium [23,30]. The cells used for the test 
are rich in mucin content, an important feature also to evaluate the effect of chitosan coating on 
the permeation. 
After Alcian-blue PAS reaction, Caco-2 cells appeared stained in magenta, highlighting the 
presence of neutral mucins (Figure 6). This kind of mucins usually reacts with PAS. The lack 
of blue staining highlighted the absence of acid mucins [65].
A first set of experiments was performed to select the suitable dilution of NPs dispersions for 
further studies, i.e., permeation and uptake experiments. For this purpose, cell viability (MTS) 
assay was carried out. As reported in Figure 7 (panel a), when Caco-2 cells were exposed for 4 
h to different concentrations of SulfB-HSA NPs and SulfB-CS-HSA NPs (dilution from 1:40 to 
1:10) the cell viability was not reduced. Further experiments demonstrated that when the cells 
were incubated with the two types of SulfB-NPs for 24 h, diluted 10 times, the cell viability was 
not significantly affected compared to the control group (Figure 7, panel b).
Since the developed formulations are designed for nasal administration, and the nasal 
epithelium represents the first barrier, these results demonstrate their biocompatibility, 
independently of the surface charge. 
The permeation studies across the Caco-2 monolayer revealed that the Papp values of SulfB-HSA 
NPs and SulfB-CS-HSA NPs were similar for the first 3 hours (Figure 8). This is probably 
related to the mucoadhesive characteristics that CS conveys to the NPs. A delayed drug release 






























































of SulfB-CS-HSA NPs was higher, about twice the Papp value of SulfB-HSA NPs (Figure 8). 
Finally, the obtained Papp results are useful for in vitro prediction, as confirmed by the recovery 
values, which were above 80% in all experiments [27].
To elucidate the endocytic uptake mechanism and to differentiate SulfB-HSA NPs and SulfB-
CS-HSA NPs, the uptake experiments were carried out in the presence of sodium azide as 
energy depletion agent, chlorpromazine, a clathrin-dependent endocytosis inhibitor and 
indomethacin, as caveolin-dependent endocytosis inhibitor. As evidenced in Figure 9, the 
cellular uptake of both NPs was significantly inhibited in the presence of sodium azide, 
chlorpromazine and indomethacin with a more pronounced effect of all the inhibitors in the 
case of uncoated NPs. These data indicated that both formulations, were internalized by energy-
dependent mechanism and the clathrin-mediated endocytosis resulted the main pathway 
involved in the uptake, consistent with the results obtained in other works with similar 
formulations [68]. 
3.8 hCMEC/D3 experiments
The possible toxic effects of the NPS were evaluated by MTT and LDH assays in hCMEC/D3 
cell line (Figure 10). The same cells were used for permeability studies. When cells were 
exposed to HSA NPs and CS-HSA NPs (from dilution 1:500, 1:100 and 1:10) for 2 and 24 h, 
no significant changes were observed in MTT metabolism, or LDH release respected to cells 
incubated with only complete medium indicating that HSA NPs and CS-HSA NPs did not affect 
the metabolic activity of the cells nor the membrane integrity.
A lot of study use the hCMEC/D3 cell line as a model of the human BBB and in particular for 
to understand the drug transport mechanisms [15, 27]. As the cells retain the expression of most 
transporters and receptors expressed in vivo, the permeability studies were performed to predict 
the permeability of SulfB-HSA NPs and SulfB-CS-HSA NPs across the BBB, after a possible 
absorption via the respiratory epithelium and achievement of the circulation, as indirect 
pathway for the NTB delivery. NaF was used as negative control and its Papp was calculated to 
monitor the integrity of the cell layer, together with the phase-contrast microscopy [28]. 
The permeation studies across hCMEC/D3 monolayer revealed that the Papp value of SulfB-CS-
HSA NPs was higher than with SulfB-HSA NPs at 1 and 2 hours (Figure 11), this effect perhaps 
is in part due to the mechanism of action of CS which induces a reversible transient change of 
the tight junctions. However, after 3 h of incubation, the Papp values of SulfB-CS-HSA NPs and 






























































To understand the possible endocytic uptake mechanism of the two different formulations, the 
sodium azide, as energy depletion agent, the chlorpromazine, a clathrin-dependent endocytosis 
inhibitor and the indomethacin, as caveolin-dependent endocytosis inhibitor, were used. As 
evidenced in Figure 12, the cellular uptake of SulfB-HSA NPs and SulfB-CS-HSA NPs was 
significantly reduced in the presence of all three inhibitors with a greater effect in the case of 
uncoated NPs. These data indicate that both formulations were internalized in an energy-
dependent manner and the clathrin-mediated endocytosis was the main pathway involved in 
this uptake.
3.9 Effects of nanoparticles on tight and gap junctions expression
Chitosan induced a significant decrease of the expression of gap junctions in hCMEC/D3 cells, 
but not in tight junctions in Caco-2 (data not shown). Exposure of the two cell lines to CS-HSA 
NPs at the 1:10 dilution for 2 h caused a decrease in the levels of ZO-1 expression significantly 
for hCMEC/D3, but not for Caco-2. However, HSA NPs did not alter the level of the protein 
(Fig. 13). In the hCMEC/D3 cells CS-HSA NPs decreased also the levels of Caudin-5 and Ve-
Cadherin that are the most abundant gap junctions in these cells [27] (Fig.13). The different 
effect observed with the NPs in the two cell lines can depend on the different mechanisms of 
action of chitosan: its effect on the gap junctions in the case of hCMEC/D3 cells, while the 
mucoadhesion in the case of Caco-2.
Variations of tight junctions (TJP1) expression were assessed also at RNA level, by RT-PCR. 
As shown in Figure 14 (panel a), the exposure to CS-HSA NPs and, at a lesser extent, to HSA 
NPs for 2 hours, significantly reduced the expression of ZO1 in hCMEC/D3 cells while these 
formulations did not significantly alter its expression in Caco-2 cells, confirming the findings 
obtained at the protein level (Fig. 13). The qualitative PCR confirmed the data obtained and 
shown in real time PCR (Fig. 14, panel b).
Overall, these data indicate that CS-HSA NPs have advantages in opening the tight junctions 
between hCMEC/D3 cells, a model of blood-brain barrier, allowing for the transport of 
molecules across the barrier. The effect on Caco-2 cells, on the contrary, indicated that these 
formulations can be safely used for nasal administration because intact epithelial tight junctions 






























































3.10 Ex vivo transport experiments across rabbit nasal mucosa
The ex vivo permeation of SulfB from SulfB-HSA NPs, SulfB-CS-HSA NPs and aqueous 
solution was studied by using rabbit nasal mucosa as biological barrier [42-44]. The maximum 
permeation of SulfB in 24 h was 83.7% for CS-HSA NPs, 68.9% for HSA NPs and 45.5% in 
the case of the aqueous solution of the dye (Figure 13). The higher permeation of SulfB, when 
loaded into CS-HSA NPs could be due to the permeation enhancing activity of CS, in particular 
to the interaction of positively charged amino groups of CS with negatively charged cell 
membranes and to the opening of the tight junctions, as evidenced in the experiments with 
Caco-2 and hCMEC/D3 cells. On the other hand, the possible reason for the lower permeation 
of the free-SulfB in comparison to SulfB loaded into HSA NPs and CS-HSA NPs could be due 
to the hydrophilic nature of drug [49].
Besides, the apparent permeability coefficient of SulfB loaded into CS-HSA NPs resulted 16.7 
± 1.3 x 10-6 cm/s, while the permeation rates of HSA NPs and free-SulfB resulted 13.8 ± 1.1 x 
10-6 cm/s and 9.1 ± 0.1 x 10-6 cm/s, respectively. A greater permeability coefficient is expected 
to correlate with enhanced absorption [69]. The obtained data are suitable for an accurate 
prediction since the mass balance values were 98.9  1.6 % for SulfB-HSA NPs and 99.6  0.6 
% for SulfB-CS-HSA NPs.
The CS coating on the surface of HSA NPs determined a slower amount of SulfB permeated in 
particular during the first 6 hours, in comparison to uncoated NPs (Figure 15). This result is 
due to the mucoadhesive properties of CS-HSA NPs, which could result in an extended time of 
action, in accordance with the results obtained by the in vitro release studies and Caco-2 
experiments [51,56,64,66,67].
The mucoadhesive properties of SulfB-CS-HSA NPs compared to SulfB-HSA NPs were also 
evidenced by the experiment performed for 4 h. As hypothesized, concerning the amount of 
SulfB recovered into the rabbit nasal mucosa after 4 h, CS-HSA NPs exhibited higher SulfB 
accumulation (6.7%) compared to HSA NPs (1.7%). These results demonstrated the strong 
interaction between CS and the mucin.
4. Conclusion
In this study, the influence of CS-coating on HSA NPs for nasal delivery was investigated for 
the first time. Concerning physical and chemical parameters, the use of chitosan-coated 
nanoparticles is a promising approach for nose-to-brain drug delivery. The freeze-drying 






























































suspensions, at 4°C, and as freeze-dried products. The functionalization coating with CS was 
confirmed by the difference in the ζ-potential value and also by TEM analysis. Besides, the 
mucoadhesive properties of CS and its ability to modulate the release of the entrapped molecule 
were proved by the turbidimetric and the indirect method and performing in vitro release 
studies. Caco-2 and hCMEC/D3 cell experiments, selected as model of nasal epithelium and 
BBB, respectively, evidenced the safety of the NPs and the ability of CS to increase the drug 
permeation. Both formulations were internalized into the cells with the energy-dependent 
mechanism, and the clathrin-mediated endocytosis was found to be the main pathway involved 
in this process. 
The possible effects of the two formulations on tight and gap junctions expression were 
assessed in both cellular lines. CS-HSA NPs have the advantage of opening the tight junctions 
between hCMEC/D3 cells, by decreasing the levels of ZO-1 expression, allowing for the 
transport of molecules across the barrier. The effect was not evidenced in the Caco-2 cells. The 
different effect observed with the NPs in the two cell lines may be dependent on the different 
mechanisms of action of CS, in the case of hCMEC/D3 cells dependent on the gap junctions 
while in the case of Caco-2 on the mucoadhesion.
Ex-vivo studies using rabbit nasal mucosa demonstrated a strong interaction between CS and 
the mucosa and the higher penetrating potential of CS-HSA NPs respect to uncoated NPs. 
Consequently, the present research proposed a novel and promising strategy based on HSA NPs 
surface modification for the NTB delivery of many bioactives.
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Figure 1. TEM image of HSA NPs. 
Figure 2. TEM image of CS-HSA NPs. 
Figure 3. Turbidimetric method. Absorbance difference of mucin admixed with HSA NPs and CS-
HSA NPs. Data displayed as mean ± SD; n=3. ** p < 0.01 vs. HSA NPs (ANOVA + Tukey’s test).
Figure 4. Indirect method. -potential of HSA NPs and CS-HSA NPs after incubation with mucin. 
Data displayed as mean ± SD; n=3.
Figure 5. In vitro release profiles of SulfB solution, SulfB-loaded HSA NPs and SulfB-loaded CS-
HSA NPs in PBS. Data displayed as mean ± SD; n=3.
Figure 6. Mucins identification by Alcian-blue PAS staining. Left panel: representative images of 
Caco-2 cells x400 magnification. Right panel: detail of left panel (x1000 magnification). Scale 
bar:100 µm.
Figure 7. Caco-2 cell viability evaluated by MTS assay after exposure for 2 h (a) and 24 h (b) to 
HSA NPs and CS-HSA NPs. Data are expressed as percentage of control (untreated group). Values 
represent the mean ± SEM of at least three experiments performed in triplicate. 
Figure 8. Permeation studies across Caco-2 cells. Data displayed as mean ± SD; n=3. ** p < 0.01 vs 
HSA NPs. (ANOVA + Tukey’s test).
Figure 9. Effect of different inhibitors on Caco-2 cell internalization pathways of HSA NPs and CS-
HSA NPs. Data displayed as mean ± SD; n=3. ** p < 0.01 vs. 37°C; #, @, °° p < 0.05 vs. CS-HSA 
NPs. (ANOVA + Tukey’s test).
Figure 10. hCMEC/D3 cell viability evaluated by MTT assay (right panel) and cytotoxicity by LDH 
assay (left panel) when exposed for 2 h (a), and 24 h (b) to HSA NPs and CS-HSA NPs. Data are 
expressed as percentage of control (EBM-2 medium) and Triton-X which represent, respectively, the 
maximum cell viability and cell cytotoxicity. Values represent the mean ± SEM of at least three 
experiments performed in triplicate. ** p < 0.01 vs. EBM-2 alone.
Figure 11. Permeation studies across hCMEC/D3 cells. Data displayed as mean ± SD; n=3. * p < 
0.05 vs HSA NPs. (ANOVA + Tukey’s test).
Figure 12. Effect of different inhibitors on hCMEC/D3 cell internalization pathways of HSA NPs 
and CS-HSA NPs. Data displayed as mean ± SD; n=3. ** p < 0.01 vs. 37°C; * p < 0.05 vs. 37°C. 
(ANOVA + Tukey’s test).
Figure 13. Effect of HSA NPs and CS-HSA NPs on the gap junctions in hCMEC/D3 cells. Data 
displayed as mean ± SD; n=3. * p < 0.05 vs. CRL. (ANOVA + Tukey’s test).
Figure 14. (a) Results of the RT-PCR analyses on RNA extracted from Caco-2 and hCMEC/D3 cells 
exposed to HSA NPs and CS-HSA NPs, for 2 hours. Data are means±SE; n=3. **p<0.01 and 
***p<0.0001 vs control (b) Representative analysis of TJP1 expression in hCMEC/D3 and CaCo-2 
cells. PCR products were separated on 1.8% agarose gel containing Safeview. 
Figure 15. Ex-vivo permeation studies of SulfB solution, SulfB-HSA NPs and SulfB-CS-HSA NPs 
conjugates through rabbit nasal mucosa. Data displayed as mean ± SD; n=3. ** p < 0.01 vs. SulfB 
solution; * p < 0.05 vs. SulfB solution. (ANOVA + Tukey’s test).







